investors Relations



BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Drug Discovery

BenevolentAI has a proven track-record of scientifically validated discoveries. The Benevolent Platform™ powers  a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA.

disease area
target id
chemistry & lead optimization
BEN2293 | atopic dermatitis
BEN8744 | ulcerative colitis
BEN9160 | amyotrophic lateral sclerosis
glioblastoma multiforme
inflammatory bowel diseases
atopic dermatitis
ulcerative colitis
amyotrophic lateral sclerosis
inflammatory bowel diseases
glioblastoma miltiforme
View Full Pipeline

Press Releases

BenevolentAI & Odyssey Combination

Presentations & Webcasts

Corporate Governance

Press Releases
& Events

all press releases→

Latest News

Nov 4, 2022

BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.

Oct 6, 2022

Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.


Nov 17, 2022

Nick Keher, BenevolentAI’s CFO, is scheduled to present at 10.20 AM on Thursday 17th November at the upcoming Jefferies London Healthcare Conference.

Oct 19, 2022

Joanna Shields, CEO of BenevolentAI, will speak at the Apex EMEA Family Office Symposium in a panel moderated by Ben Thorpe of Goldman Sachs.